Negative Predictive Value of Surveillance PET/CT in Head and Neck Squamous Cell Cancer
M. McDermott(New York University), Barton F. Branstetter(University of Pittsburgh Medical Center), Tanya J. Rath(University of Pittsburgh), Dwight E. Heron(Bon Secours Mercy Health), Jonas T. Johnson(University of Pittsburgh), Gregory J. Kubicek(Cooper University Hospital), James Ohr(University of Pittsburgh), Marion A. Hughes(University of Pittsburgh Medical Center), Robert L. Ferris(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), S.W. Kim
Cited by 65
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590